-$0.58 EPS Expected for Evelo Biosciences, Inc. (NASDAQ:EVLO) This Quarter

Equities research analysts forecast that Evelo Biosciences, Inc. (NASDAQ:EVLOGet Rating) will report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Evelo Biosciences’ earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.57). Evelo Biosciences reported earnings of ($0.55) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 5.5%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Evelo Biosciences will report full-year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($2.31) to ($2.01). For the next year, analysts expect that the business will post earnings of ($2.16) per share, with EPS estimates ranging from ($2.63) to ($1.75). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Evelo Biosciences.

Evelo Biosciences (NASDAQ:EVLOGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.07. During the same quarter in the previous year, the firm posted ($0.62) earnings per share.

Separately, Zacks Investment Research cut shares of Evelo Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 30th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.38.

EVLO stock opened at $2.46 on Friday. The firm’s 50-day moving average price is $2.99 and its two-hundred day moving average price is $5.52. Evelo Biosciences has a 12-month low of $2.05 and a 12-month high of $17.13. The stock has a market capitalization of $131.99 million, a price-to-earnings ratio of -1.06 and a beta of 1.75. The company has a current ratio of 4.09, a quick ratio of 4.09 and a debt-to-equity ratio of 5.37.

Several institutional investors and hedge funds have recently made changes to their positions in the company. AE Wealth Management LLC boosted its stake in shares of Evelo Biosciences by 14.1% during the 3rd quarter. AE Wealth Management LLC now owns 16,077 shares of the company’s stock valued at $113,000 after purchasing an additional 1,990 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Evelo Biosciences by 0.8% during the 4th quarter. Northern Trust Corp now owns 300,436 shares of the company’s stock valued at $1,824,000 after purchasing an additional 2,300 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Evelo Biosciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 523,575 shares of the company’s stock valued at $3,178,000 after purchasing an additional 2,858 shares in the last quarter. Citigroup Inc. boosted its stake in shares of Evelo Biosciences by 62.9% during the 4th quarter. Citigroup Inc. now owns 9,356 shares of the company’s stock valued at $57,000 after purchasing an additional 3,614 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its stake in shares of Evelo Biosciences by 82.4% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,858 shares of the company’s stock valued at $61,000 after purchasing an additional 4,002 shares in the last quarter. 92.20% of the stock is currently owned by hedge funds and other institutional investors.

Evelo Biosciences Company Profile (Get Rating)

Evelo Biosciences, Inc, a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19.

Featured Stories

Get a free copy of the Zacks research report on Evelo Biosciences (EVLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.